Study of circulating IgG antibodies to BIRC5 and MYC in non-small cell lung cancer  by Ye, Leiguang et al.
FEBS Open Bio 5 (2015) 809–812journal homepage: www.elsevier .com/locate / febsopenbioStudy of circulating IgG antibodies to BIRC5 and MYC in non-small cell
lung cancerhttp://dx.doi.org/10.1016/j.fob.2015.09.007
2211-5463/ 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: cAg, control antigen; ELISA, enzyme-linked immunosorbent
assay; hAgs, human antigens; NC, negative control; NSCLC, non-small cell lung
cancer; OD, optical density; QC, quality control; SBI, specific binding index; TAAs,
tumor-associated antigens
⇑ Corresponding authors at: Department of Pulmonary Oncology, Third Affiliated
Hospital of Harbin Medical University, 150 Haping Road, Harbin 150040, China.
Tel./fax: +86 0451 86298727 (Y. Yu). Department of Radiation Oncology, Fourth
Affiliated Hospital, China Medical University, No. 4 Chongshan East Road, Shenyang
110032, China. Tel.: +86 18900913022; fax: +86 2462043117 (W. Wang).
E-mail addresses: yuyan@ems.hrbmu.edu.cn (Y. Yu), wwl822@163.com
(W. Wang).Leiguang Ye a, Weili Wang b,⇑, Cairen Chen c, Qingyong Meng c, Yan Yu a,⇑
aDepartment of Pulmonary Oncology, Third Affiliated Hospital of Harbin Medical University, Harbin 150040, China
bDepartment of Radiation Oncology, Fourth Affiliated Hospital, China Medical University, Shenyang 110032, China
c School of Clinical Laboratory Science, Guangdong Medical College, Dongguan 523808, Chinaa r t i c l e i n f o
Article history:
Received 9 August 2015
Revised 11 September 2015







Tumor immunitya b s t r a c t
An in-house enzyme-linked immunosorbent assay (ELISA) was developed in this study to detect cir-
culating IgG antibodies to peptide antigens derived from baculoviral IAP repeat-containing protein 5
isoform 2 (BIRC5) and myc proto-oncogene protein (MYC) in non-small cell lung cancer (NSCLC).
Student’s t-test revealed that circulating anti-MYC IgG levels were significantly increased in patients
with NSCLC compared with control subjects in the discovery sample (t = 3.96, P = 0.0001) but not in
the validation sample (t = 1.24, P = 0.217), generating a combined P-value of 0.0003. Neither the dis-
covery sample nor the validation sample showed a significant change in anti-BIRC5 IgG levels in
NSCLC. Further analysis was performed to investigate whether circulating IgG antibodies to these
two tumor-associated antigens (TAAs) significantly changed with early (stages I + II) and late (stages
III + IV) NSCLC stages. The results showed that neither anti-MYC IgG nor anti-BIRC5 IgG levels signif-
icantly changed in patients with early stage NSCLC, while patients with late stage NSCLC had higher
levels of circulating anti-MYC IgG than control subjects in the discovery sample (t = 4.74, P < 0.0001)
but not in the validation sample (t = 0.80, P = 0.423), generating a combined P-value of 0.00003
(X2 = 26.13, df = 4). In conclusion, circulating IgG antibodies to MYC and BIRC5 do not appear to serve
as biomarkers for early diagnosis of lung cancer but anti-MYC IgG might have a prognostic value.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lung cancer is the most frequently diagnosed malignant tumor
and the leading cause of cancer-related deaths for both men and
women. An estimated 1.8 million new cases with lung cancer
occurred in 2012, accounting for about 13% of total cancer diag-
noses worldwide [6,20]. In China, the incidence of lung cancer is
approximately 19% of all cancers diagnosed in recent years [2].
Of all lung cancer cases, more than 80% are likely to suffer from
non-small cell lung cancer (NSCLC), including squamous cellcancer, adenocarcinoma and large cell cancer. Patients with early
stage lung cancer may be curable so that there is an urgent need
to develop early diagnosis tool for screening of the individuals at
a high risk.
It has been suggested that circulating autoantibodies to tumor-
associated antigens (TAAs) can serve as potential biomarkers for
early diagnosis of malignant tumors [15,19,9,5,12,13]. A successful
test has been developed for early diagnosis of lung cancer although
the improvement of its sensitivity and specificity remains needed
[10,1,7]. Identification of more TAAs will be the solution to
enhance the panel positivity in early stage lung cancer. Increased
levels of circulating antibodies to survivin, also called baculoviral
IAP repeat-containing protein 5 (BIRC5), and to myc proto-
oncogene protein (MYC) have been reported in lung cancer
[14,8]. A recent study tested the levels circulating IgG against
BIRC5 and MYC in breast cancer and revealed that the levels of
these two autoantibodies were significantly higher in patients with
early stage breast cancer than control subjects [22]. The present
study was then designed to detect circulating IgG antibodies to
BIRC5 and MYC among patients with non-small cell lung cancer
(NSCLC) and control subjects in a Chinese population.
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2.1. Subjects
A total of 109 patients who were newly diagnosed as having
NSCLC were recruited by the Fourth Affiliated Hospital of China
Medical University, Shenyang, China, in the period between March
2013 and November 2014. Of these 109 patients aged
62.1 ± 10.4 years, 70 were male and 39 were female; they were
divided into the discovery samples (n = 49) that were collected
during 2013 and the validation samples (n = 60) that were col-
lected during 2014. Their diagnosis and tumor staging were made
based on radiographic examination and histological confirmation;
inclusion of patients was restricted to those with adenocarcinoma
and squamous carcinoma only. Based on NSCLC staging informa-
tion, these patients were divided into two subgroups, the early
stage group (stages I + II) and the late stage group (stages III
+ IV). Blood samples were taken prior to any anticancer treatment.
A total of 216 healthy subjects, well matched in age
(59.1 ± 3.5 years) and smoking history, were also recruited from
local communities, 108 of whom were used as controls for the
discovery samples and 108 for the validation samples. Clinical
interview and radiographic examination were applied to rule out
the control subjects who had history of lung cancer or any other
malignant tumors. All the subjects were of Chinese Han origin
and they all gave informed written consent to participate in this
study as approved by the Ethics Committee of the Fourth Affiliated
Hospital of China Medical University, and conformed to the
requirements of the Declaration of Helsinki.
2.2. Antibody testing
An enzyme-linked immunosorbent assay (ELISA) was devel-
oped in-house using linear peptide antigens derived from human
BIRC5 and MYC proteins as described in a previous study [22]; a
peptide fragment derived from a maize protein (NCBI: 1BFA_A)
was used as the control antigen (cAg). The sequence information
of these three peptides is given in Table 1. Briefly, both hAgs and
cAg were synthesized by solid-phase chemistry with purity of
>95%, and then applied to develop a relative ELISA test for detec-
tion of circulating IgG antibodies to ANXA1 and FOXP3. Synthetic
peptides were dissolved in 67% acetic acid to obtain a concentra-
tion of 5 mg/ml (stock solution kept at 20 C), and were diluted
with phosphate-buffered saline (PBS)-based coating buffer
(P4417, Sigma–Aldrich) containing 0.1% sodium azide. Coaster
96-Well Microtiter EIA Plates (ImmunoChemistry Technologies,
USA) were half-coated in 0.1 ml/well of each hAg and half-coated
in 0.1 ml/well of cAg. The antigen-coated 96-well microplate was
incubated overnight at 4 C. After the plate was washed 3 times
with wash buffer made from Tris-buffered saline with Tween20
(T9039, Sigma–Aldrich), 100 ll plasma sample diluted 1:150 in
assay buffer (PBS containing 1.5% BSA) was added and 100 ll assay
buffer was also added to the negative control (NC) wells. Following
2 h incubation at room temperature, the plate was washed 3 times
and 100 ll peroxidase-conjugated goat antibody to human IgG
(A8667, Sigma–Aldrich) diluted 1:30,000 in assay buffer was added
to each well. After incubation at room temperature for an hour,Table 1
Information of peptide antigens used for development of ELISA antibody test.
Antigen Sequence (N ? C)
BIRC5 H-dflkdhristfknwlhhfqglfpgatslpv-OH
MYC H-rvkldsvrvlrqisnnrkcfellptpplsps-OH
Control H-haqlegrlhdlpgcprevqrgfaatlvtn-OHcolor development was initiated by adding 100 ll Stabilized
Chromogen (SB02, Life Technologies) and terminated 25 min later
by adding 50 ll Stop Solution (SS04, Life Technologies). The mea-
surement of the optical density (OD) was completed within
10 min at 450 nm with a reference wavelength of 620 nm. To
reduce the interference from a non-specific signal produced by
passive absorption of various IgG antibodies in plasma to the sur-
face of 96-well microplate, a specific binding index (SBI) was used
to express the levels of circulating antibodies to BIRC5 and MYC.
Each sample was tested in duplicate and SBI was calculated as
follows:
SBI ¼ ðODhAg  ODNCÞ=ðODcontrol antigen  ODNCÞ:2.3. Data analysis
Antibody-testing data were expressed in mean ± standard devi-
ation (SD) in SBI. Student’s t-test was applied to examine the differ-
ence in SBI between the patient group and the control group, and
the Fisher’s method of combining P-value as introduced by Elston
[4] was applied to work out combined P-values based on 2
t-tests performed on the discovery samples and the validation
samples and on the early stage group and the late stage group.
To minimize intra-assay deviation, the ratio of the difference
between duplicated OD values to their sum was used to assess
the precision for assay of each sample. If the ratio was found to
be >15%, the test of this sample was treated as being invalid and
would not be used for data analysis. The inter-assay deviation
was estimated using a pooled plasma sample, namely quality con-
trol (QC) sample, which was randomly collected from >100 unre-
lated healthy subjects.
3. Results
Student’s t-test revealed that circulating anti-MYC IgG levels
were significantly increased in patients with NSCLC compared with
control subjects in the discovery sample (t = 3.96, P = 0.0001) but
not in the validation sample (t = 1.24, P = 0.217), generating a com-
bined P-value of 0.0003 (X2 = 21.19, df = 4). Neither the discovery
sample nor the validation sample showed a significant change in
circulating anti-BIRC5 IgG levels in NSCLC (Table 2).
As shown in Table 3, neither anti-MYC IgG nor anti-BIRC5 IgG
levels significantly changed in the patients with early stage NSCLC
whereas patients with late stage NSCLC had higher levels of circu-
lating anti-MYC IgG than control subjects in the discovery sample
(t = 4.74, P < 0.0001) but not in the validation sample (t = 0.80,
P = 0.423), generating a combined P-value of 0.00003 (X2 = 26.13,
df = 4). Neither the discovery sample nor the validation sample
showed a significant change in circulating anti-BIRC5 IgG levels
in late stage NSCLC (Table 4).4. Discussion
This study suggests that circulating anti-MYC IgG instead of
anti-BIRC5 IgG levels were significantly increased in NSCLC
(Table 2), but the altered anti-MYC IgG levels were observed only





The levels of circulating IgG antibodies to BIRC5 and MYC in NSCLC.
Sample Patient (n) Control (n) t1 P2
Discovery
BIRC5 0.87 ± 0.14 (49) 0.90 ± 0.42 (108) –0.43 0.665
MYC 0.86 ± 0.30 (49) 0.72 ± 0.14 (108) 3.96 0.0001
Validation
BIRC5 0.78 ± 0.19 (60) 0.77 ± 0.37 (108) 0.13 0.894
MYC 0.90 ± 0.27 (60) 0.86 ± 0.16 (108) 1.24 0.217
The antibody levels are expressed as mean ± SD in SBI.
1 Student’s t-test (two-tailed).
2 Combining probabilities: X2 = 1.04, df = 4, P = 0.904 for anti- BIRC5 IgG levels
and X2 = 21.19, df = 4, P = 0.0003 for anti-MYC IgG levels.
Table 3
The levels of circulating IgG antibodies to BIRC5 and MYC in early stage NSCLC.
Sample Patient (n) Control (n) t1 P2
Discovery
BIRC5 0.87 ± 0.16 (15) 0.90 ± 0.42 (108) –0.21 0.832
MYC 0.74 ± 0.12 (15) 0.72 ± 0.14 (108) 0.49 0.623
Validation
BIRC5 0.75 ± 0.14 (21) 0.77 ± 0.37 (108) –0.21 0.834
MYC 0.92 ± 0.12 (21) 0.86 ± 0.16 (108) 1.56 0.120
The antibody levels are expressed as mean ± SD in SBI.
1 Student’s t-test (two-tailed).
2 Combining probabilities: X2 = 0.73, df = 4, P = 0.947 for anti-BIRC5 IgG levels and
X2 = 5.19, df = 4, P = 0.269 for anti-MYC IgG levels.
Table 4
The levels of circulating IgG antibodies to BIRC5 and MYC in late stage NSCLC.
Sample Patient (n) Control (n) t1 P2
Discovery
BIRC5 0.87 ± 0.13 (34) 0.90 ± 0.42 (108) –0.38 0.702
MYC 0.90 ± 0.34 (34) 0.72 ± 0.14 (108) 4.74 <0.0001
Validation
BIRC5 0.79 ± 0.21 (39) 0.77 ± 0.37 (108) 0.32 0.752
MYC 0.89 ± 0.32 (39) 0.86 ± 0.16 (108) 0.80 0.423
The antibody levels are expressed as mean ± SD in SBI.
1 Student’s t-test (two-tailed).
2 Combining probabilities: X2 = 1.28, df = 4, P = 0.865 for anti-BIRC5 IgG levels and
X2 = 26.13, df = 4, P = 0.00003 for anti-MYC IgG levels.
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lung cancer remains in debate although some of them may have a
prognostic value.
The MYC protein is a transcription factor and plays a role in cell
cycle progression, apoptosis and cellular transformation. The
mutation of the MYC gene has been found in many cancers, leading
to its persistent expression that can then regulate the expression of
many genes involved in cell proliferation and resulting in the for-
mation of cancer. Studies of MYC showed that there was an
increase in MYC expression in NSCLC [16] and increased MYC
expression was related to poor prognosis of the malignancy [11].
A question is what is the biological significance of increased
anti-MYC antibody levels in NSCLC? It is possible that increased
anti-MYC IgG levels may be protective against the role of MYC in
the development of lung cancer. While the mechanism behind
the increased anti-MYC IgG levels in NSCLC is unknown, humoral
immune responses to TAAs may be induced by a self-
immunization process linked to increased immunogenicity of
MYC during malignant transformation, including antigen mutation
[18], overexpression [3], altered antigen folding [17] and aberrant
degradation [21]. Further investigation will clarify the complicatedmechanism involved in triggering the secretion of anti-MYC IgG
antibodies in lung cancer.
5. Conclusion
Circulating IgG antibodies to MYC and BIRC5 do not appear to
serve as biomarkers for early diagnosis of lung cancer although
anti-MYC IgG may have a prognostic value.
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